Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The U.S. FDA's approval of Millennium Pharmaceuticals' Velcade (bortezomib) injection indicated for first-line treatment of multiple myeloma comes as no surprise to those analyzing the pharmaceutical industry